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ABSTRACT. Operative manipulation of blood vessels might lead to spasm, thereby destroying the endothelial 
cell function: the spasm can be prevented by the vasodilator papaverine. To study if this was mediated via the 
prostanoid pathway the following investigation was undertaken: canine jugular veins and carotid arteries were 
dissected with or without papaverine. Vessel segments were then perfused with Hank’s balanced salt solution 
for five times 15 min. Prostacyclin was measured as the stable degradation product 6-keto-PGF,, and 
thromboxane as TXB2, by radioimmunoassay. Control arterial segments’ 6-keto-PGF,, release was initially 
129.5 + 20.1 pg/mm’/lS mitt, and 29.7 + 10.4 after 60 min (pcO.05 vs initial value) and responded to arachidonic 
acid (AA) with an increase to 139.2 * 23.1 pg/mm2/15 min (pcO.05). Segments treated with papaverine had the 
same release as the controls. In venous segments there was a lower initial release (pcO.05) from segments given 
papaverine than from controls, but this was more likely an effect of papaverine on the assay. There was no 
difference in release of prostacyclin from segments given papaverine in the perfusate compared to controls 
when using “‘1 tracer. When using 3H tracer including absorption of free antigen to dextran coated charcoal, 
papaverine displaced the free tracer giving artificially low values. There was no effect of papaverine given 
intraoperatively on the TXB, release, neither from arteries nor from veins. In another experiment the vessel 
wall tension was examined and the cyclooxygenase inhibitor diclofenac did not inhibit the vasodilating effect of 
papaverine. It is concluded that the vasodilating effect of papaverine is not mediated via prostacyclin release 
and that the vasodilating effect does not influence the prostacyclin release from arteries or veins. Finally, 
papaverine interacts with the 3H assay by displacing the antigen-antibody complex. 
INTRODUCTION 
Vein grafts are sometimes complicated by thrombosis 
although not as often as synthetic grafts used in the same 
position. One reason suggested for the development of 
thrombosis has been that spasm of the harvested vein 
disturbs the endothelial cell function with interruption 
of the endothelial cellular line as well as destruction of 
the endothelial cells (l-3). Harvested veins have dis- 
played endothelial cellular disruption and intimal thick- 
ening (4-6). Endothelial denudation increases intimal 
thickening (7). Papaverine acts as a smooth muscle 
relaxant and the use of papaverine before vein harvest 
decreased endothelial damage and intimal thickening 
(8-10). Theoretically this relaxation could be mediated 
through the arachidonic acid pathway. The two pros- 
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tanoids prostacyclin and thromboxane are both involved 
in the regulation of thrombosis and haemostasis. 
Prostacyclin is the most potent vasodilator and inhibitor 
of platelet aggregation known and is the main prostanoid 
from the endothelial cell (11). Thromboxane is a potent 
vasoconstrictor and platelet aggregator and is mainly 
derived from platelets (11) but also from the vascular 
wall (12). Papaverine has been reported to block the 
release of phospholipids in platelets (27). 
Perfusion of vessels ex vivo gives rise to an initial 
burst in prostacyclin and thromboxane release with a 
rapid decline and relatively stable release for 3 h 
(13-14). If AA (arachidonic acid) is provided to the 
perfusate, either immediately, after 1 h or after 6 h, there 
is an increased release of prostanoids (14). 
The objective of this investigation was to study if 
papaverine, given perioperatively or directly to the 
perfusate, would influence the prostanoid release from 
the vascular wall in ex vivo perfused canine arteries 
and veins, and if any inhibitory action was at the 
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phospholipase level. Furthermore, the aim was to study 
if the dilating effect of papaverine could be blocked by 
a cyclooxygenase inhibitor. 
MATERIALS AND METHODS 
Operative procedure 
Six adult mongrel dogs were anesthetized with pento- 
barbital (20 mg/kg bw), intubated and mechanically 
ventilated. External jugular veins and carotid arteries 
were exposed through a midline neck incision. On one 
side 5-10 ml papaverine hydrochloride (0.6 mg/ml: 
Sigma) was injected around and into the vascular sheath, 
without penetrating the vessel. The vessel was gently 
dissected free and all tributaries were ligated. On the 
contralateral side, exactly the same procedure was per- 
formed but without administration of papaverine. Seven 
other mongrel dogs were used for the study of the effect 
of papaverine given directly to the perfusate and were 
operated upon as when harvesting the control segments. 
Animal care in this study was carried out in accordance 
with the ‘Principles of Laboratory Animal Care’ and 
‘Guide for the Care of and Use of Laboratory Animals’ 
(NIH Publication No 80-23, revised 1978). The vessels 
were then rinsed and flushed with room temperate 
calcium and magnesium-free Hank’s balanced salt solu- 
tion (CMF-HBSS; Gibco Laboratories, Grand Islands, 
NY, pH 7.4, 290 mOsm) until the effluent was clear. 
After excision, veins retracted to about half of their in 
situ length, whereas the arteries retracted to two-thirds 
with no difference when papaverine was given. Each 
vessel was cut into 3 cm length, and briefly stored in 
CMF-HBSS until subsequently being perfused. The 
circumference and length of the retracted segments 
were measured in order to calculate the perfused area, 
allowing prostanoid release to be adjusted for luminal 
surface area. 
Perfusion technique 
The open recirculating perfusion device has previously 
been described in detail (15, 16). Briefly, a pulsatile 
pump created a pulsatile flow that, when creating venous 
flow, was converted by a ‘windkessel device’ to a 
nonpulsatile flow. With a resistance clamp inserted after 
the vessel segment, a desired pressure was built up in the 
system and measured by a pressure recorder. The vessels 
were mounted in the perfusion system and immersed in 
a 37 “C HBSS bath. The segments were expanded to 
approximately their in situ length, but not overstretched. 
Control segments and experimental segments were 
perfused simultaneously, arteries and veins being ran- 
domly perfused as pair number one and two. Veins were 
perfused at a pressure of 7 mmHg with a mean 
nonpulsatile flow of 90 ml/min, whereas arteries were 
perfused at a pressure of 100 mmHg with a mean 
pulsatile flow of 90 ml/min. 
All segments were perfused with HBSS (37 “C. pH 
7.4, 290 mOsm) for 5 x 15 min with the exchange of 
perfusate after each time period. To the last perfusate. 
AA was given reaching a final concentration of 4 ,ug/ml. 
The perfusates were stored at -70 “C until subsequent 
radioimmunoassay (RIA). To study the effect of 
papaverine given to the perfusate. this agent was given 
in a dose of 15 mg providing a concentration of 
0.6 mg/ml. 
Extraction procedure 
Samples were extracted prior to radioimmunoassay to 
remove lipids and other potential interferents using a 
modification of procedures previously described ( 17). 
An aliquot of ‘H-TXB, (100 ~1, 0.02nCi; NET-603. 
New England Nuclear, Boston, MA) was added to each 
sample ( 1 .O ml) to monitor the extraction efficiency. An 
aliquot of acetonitrile (I .O ml) was then added to each 
sample and the protein precipitate which forms was 
discarded. The supematant was acidified with formic 
acid (0.1 ml, pH 3.5) and washed with petroleum ether 
(2 x 3 ml). The eicosanoids were then extracted from the 
aqueous layer with ethyl acetate (2 x 4 ml) The extract 
was air-dried, stored at -20 “C and redissolved in RIA 
assay buffer ( 1 .O ml; 0.1% pigskin gel, 1M PO+ 0.15M 
NaCI. pH 7.4) just before analysis. The efficiency of 
extraction of ‘H TXB, calculated from the beta radio- 
activity levels in a 0.1 ml aliquot of extracted sample, 
was used to correct the results of the subsequent 
prostaglandin immunoassays. 
3H Rudioinzn~utlousscr? 
6-Keto-PGF,,. the stable degradation product of prosta- 
cyclin. was measured using a commercially available 
reagent kit (NEK-008, New England Nuclear. Boston, 
MA). The limit of detection in the analysis was 59 pg/ml 
(f2 SD from the response in the absence of standard). 
According to the manufacturer, the relative potency of 
other prostaglandins, calculated from the concentrations 
required to reduce the binding of the tracer by 50% was 
in percentages: PGE, 2.5, PGF,, 0.3, PGE, 0.2. PGF,,, 
0.05 and TXB, <0.3 (manual New England Nuclear). 
TXB, was determined using a similar method employ- 
ing antibodies (a generous gift of the Upjohn Company. 
Kalamazoo, MI) produced according to published 
methods (19) and a commercially available tritiated 
TXB, tracer (NET-603. New England Nuclear). The 
detection limit with this method was 11.8 pg/ml. The 
relative binding potency of other prostaglandins was 
in percentages: PGD, 1.0. PGD, 1.0, PGF,, 0.04 and 
PGF, 0.04. 
‘-“I Radioimmunoassay 
6-Keto-PGF,, was also measured using a second com- 
mercial kit (NEK-025. New England Nuclear) which 
employs a i’51-labelled derivative of 6-keto-PGF,, in- 
stead of the tritiated tracer in the method previously 
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described. The sensitivity of this assay was 8.7 pg/ml 
and according to the manufacturer the cross-reactivity 
of other prostaglandins was in percentages: PGF,, 2.6, 
PGE, 1.9, TXB, 1.4, PGE? 1.1, PGF,, 0.8, PGA, 0.2, 
PGDl 0.2, PGA, 0.04, AA 0.005. 
+ standard error pg/mm?/l5 min. Analyses were per- 
formed with test of variance and the Wilcoxon signed 
rank test for paired data. A p value co.05 was considered 
significant. 
High pressure liquid chromatography RESULTS 
Reversed phase high pressure liquid chromatography 
(HPLC) according to a modification of methods previ- 
ously described (20, 2 1) was used to confirm the identity 
of immunoactivity with pure standard 6-keto-PGF,, and 
to further purify some samples. Samples (1 ml) were 
extracted according to the method described above and 
redissolved in HPLC elution solvent (200 ~1) described 
below. The entire sample was subsequently applied to 
a 4 pm C-18 column (3.9 x 150 mm Novopak, Waters, 
Milford, MA) and isocratically eluted at ambient 
temperature with acetonitrile/water (31:69 v/v with 1% 
TFA) at a flow rate of 75 ml/min. The absorbance at 
195 nm was continually monitored (SpectraFlow 773, 
Kratos Analytical Instruments, Westwood, NJ) and 
five fractions collected every min, i.e. 150 pullfraction 
(Gilson Micro fractionator, Gilson Medical Electronics. 
Middleton, WI). Fractions were air-dried, reconstituted 
in assay buffer, and appropriately diluted for subsequent 
analysis by RIA. 
In segments given papaverine prior to dissection, no 
circumferential vasoconstriction was noted. The circum- 
ferential vasoconstriction in control segments, however, 
was relieved when the segments were mounted in the 
perfusion system. 
Papaverine given prior to harvest 
Arteries (Fig. 1; 3H RIA) 
With the onset of perfusion arterial control segments 
had a burst of 6-keto-PGF,, release which reached 129.5 
f 10.1 pg/mm2/15 min and declined to the lowest value 
after 60 min (p<O.O5 vs initial value). When AA was 
given there was an increase to the initial level (~~0.05 vs 
Vascular tension 
A 2-3 mm thick slice of the rabbit carotid artery was 
mounted on a L-shaped metal prong connected to a 
Grass polygraph. The vessel segment was immersed in 
95% 0, and 5% CO? balanced Kreb’s solution. A ten- 
sion of 4 mN was applied and the vessels were allowed 
to rest for 90 minutes. After precontraction with K’ a 
segment of the vessel was given papaverine as a 
dilatatory stimulus and the other was given the cyclo- 
oxygenase inhibitor diclofenac (VoltarenR) prior to 
papaverine. The relaxation of the vessel was expressed 
in percentage of the maximal K+ contraction. 
A 
Scanning electron microscopy 
6 
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After perfusion, the vein specimens were perfusion fixed 
at 7 mmHg and the arterial specimens at 100 mmHg in 
2.5% glutaraldehyde in 0.1 M cacodylate buffer for 2 h 
followed by 24 h storage in cacodylate buffer. The 
specimens were then incubated in ethanol in increasing 
concentration up to 99.99% and then incubated in 
hexamethyldisilazane for dehydration for 10 min, dried 
in air and sputter-coated with gold-palladium (22). Five 
random areas in each specimen were investigated and 
the percentage coverage by endothelial cells was esti- 
mated and scored. No effort was made to describe the 
morphological appearance of the endothelial cells. 
B 15 30 45 60 75 
Minutes 
Statistics 
Prostanoid data in this article are expressed as mean 
Fig. 1 Prostacyclin (A) and thromboxane (B) release from arteries 
(n6) given papaverine prior to dissection, perfused at 100 mmHg and 
with a mean pulsatile flow of 90 ml/min using -‘H RIA kit. AA, 4 pg/ 
ml added. Mean f SEM. No statistically significant difference 
between controls and papaverine at any point. Wilcoxon signed rank 
test for paired data. 
*- -P ~0.05 vs initial value, **= p<O.O05 vs 60 min value. 
30 45 60 75 
Minutes 
n Artery controls 
q Artery Papaverine 
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60 min value). From segments previously treated with 
papaverine the initial release was the same as from con- 
trols (ns vs control segments) declining to the lowest 
value after 60 min (ns vs control segments). When AA 
was given, there was a significant increase almost to the 
initial value (ns vs controls). TXB, release from controls 
was initially 4.0 f 1.7 pg/mm’/lS min declining until 
60 min (ns vs initial value). After AA administration 
the release was slightly increased but without reaching 
statistical significance. TXB, release from papaverine 
segments was not statistically significantly different 
from controls. 
Veins (Fig. 2; 3H RIA) 
With the onset of perfusion the venous control seg- 
ments’ 6-keto-PGF,, release was 84.3 f 25.5 pg/mm?/ 
15 min declining to the lowest value after 60 min 
(p<O.Ol vs initial value). At that time when AA was 
given the release significantly increased to the initial 
value (~~0.05 vs 60 min value). The release from seg- 
ments given papaverine was initially 44.3 f 11.6 pg/ 
mm?/15 min (~~0.05 vs controls) declining to the lowest 
value after 60 min (ns vs controls). When AA was given 
there was an increase to a level not significantly differ- 
ent from controls. TXB, release from control segments 
was 3.1 f 1.7. 0.5 + 0.1 and 1.3 f 0.1 pg/mm’/l5 nun 
respectively, whereas the release from papaverine 
segments was 2.4 + 0.6. 0.9 f 0.3 and 1.3 f 0.1 (not 
significantly different vs controls at any point). 
Yapaverine given in the perfusate 
This study was only undertaken with Ivin segments. 
Using the ‘H RIA (Fig. 3) the initial 6-keto-PGF,, re- 
lease from control segments was 53.3 f: 13.4 pg/mm’/I 5 
min declining until 60 min (p<O.Ol vs initial value). It 
responded to AA with an increase to 95.4 f 4 1. I (p<O.Ol 
vs 60 min value). Segments given papaverine into the 
perfusate had an initial 6-keto-PGF,, release of 5.5 ? 2.5 
Vein Papaverine 
15 30 45 60 75 
Minutes 
5 
n Vein controls 
4 T Van Papaverine 
AA 
15 30 45 60 75 
Minutes 
Fig. 2 Prostacyclin (A) and thromboxane (B) release from veins 
(n6) given papaverine prior to dissection, perfused at 7 mmHg and 
with a mean nonpulsatile flow of 90 ml/min. AA. 4 pg/ml added. 
Mean f SEM. 
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Minutes 
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15 30 45 60 75 
Minutes 
Prostacyclin (A) and thromboxane (B) release. using ‘H kit. 
from vein segments (n7) given papaverine directly to the perfusate. 
AA. 4 ,ug/ml added. Mean f SEM. 
*= p<O.OS. **= ~~0.01 (Wilcoxon signed rank test for palred data). 
ND = not detectable. 
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(~~0.05 vs controls) declining to undetectable amounts 
at 60 min. When AA was given there was no response 
with detectable amounts in only two experiments, (0.5 f 
0.3 pg/mm’/l5 min) (p<O.OOl vs controls). TXB, release 
from controls was initially 5.4 f 0.8 pg/mm?/l5, also 
declining until 60 min (p<O.Ol vs initial value). It in- 
creased after addition of AA (p<O.Ol vs 60 min value). 
From segments given papaverine the TXB? release was 
lower than from controls at all points (~~0.05). 
When using the lz51 RIA (Fig. ) 4 the 6-keto-PGF,, 
release from control segments was initially 117.8 f 
25.8 pg/mm?/l5 min declining until 60 min (~~0.05 vs 
initial value). With AA the release increased to the initial 
value (p<O.O5 vs 60 min value). The 6-keto-PGF,, re- 
lease from segments given papaverine to the perfusate 
elicited the same release as the control segments. No lz51 
RIA for TXB2 was undertaken. In a separate study, 
.e 200 
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Fig. 4 Prostacyclin release, using lzsI kit, from vein segments (n7) 
given papaverine directly to the perfusate. AA, 4 pg/ml added. Mean 
+ SEM. No statistically significant difference at any point. (Wilcoxon 
signed rank test for paired data.) 
6-KETO HLPC SAMPLE ELUATES 
Sample 1 
Sample 2 
6 Keto standard 1 ug 
Tube number 
Fig. 5 HPLC of two test samples and known 6-keto-PGF,, standard. No other prostanoids than the 
immunoactive 6-keto-PGF,, peaks were detected in the test samples. 
Papaverine 11312 
- Control 
- Voltaren 1 mg/ml 
+ 8 12 16 20 24 ;” 1”’ 36 
Histamin 1 OaM Papaverine 1 Od 1 0m5 
Fig. 6 A typical relaxation curve of a rabbit aorta. When papaverine was added the relaxation 
was marked (see arrow). The addition of cyclooxygenase inhibitor indomethacin did not alter the 
dilatatory effect of papaverine. 
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papaverine was added to the dextran charcoal solution 
which displaced the bound radioactivity into the liquid 
fraction to 100% of that in the absence of prostaglandin. 
so giving high radioactivity as if there was no detectable 
6-keto-PGF,,. 
High pressure liquid chromatography (Fig. 5) 
The standard for the iodinated kit showed a somewhat 
broad spectrum with suspect double spike for the 6-keto- 
PGF,,, whereas the spike from the two samples corre- 
sponding to 6-keto-PGF,, was much thinner. No other 
spikes were found. 
Vascular tension 
A typical effect of papaverine is noted in Figure 6. The 
vessels relaxed spontaneously, but this was accelerated 
to different extents in the various segments when 
papaverine was added. Segments pretreated with cyclo- 
oxygenase inhibitors did not alter the dilatatory effect 
of papaverine. 
Scanning electron microscopy 
7590% of the endothelial cells were still present after 
the perfusion procedure. No difference was found be- 
tween the different protocols studied. No platelet aggre- 
gates were present, but single scattered platelets were 
found (Fig. 7). 
DISCUSSION 
The decline in release of prostanoids with time, when 
vessels are being perfused, is in accordance with reports 
with perfused canine vessels (1516), rabbit and rat 
aortas (23-25) and caval veins (23) as well as from 
perfused human umbilical veins ( 19). In the present 
model the vessels respond with increasing 6-keto-PGF,, 
in response to AA. thrombin and bradykinin. given 
both to each perfusate as well as given after 60 min of 
perfusion. With addition of these substances, the same 
decline in PG release is seen, but at a higher level 
compared to HBSS perfusions ( 14). The mechanism for 
this decline is discussed elsewhere (14) and will not be 
repeated here. but it seems likely to be the result of an 
accommodation rather than a run out of substrate. 
Papaverine prevented spasm in the vessels when given 
in vivo, but this administration of papaverine did not 
influence the prostacyclin release from arteries perfused 
ex vivo in the present study. It is therefore unlikely that 
the vasodilating effect of papaverine in arteries was 
mediated through the prostacyclin pathway in the 
endothelial cell. On the other hand, there was a lowet 
initial release of prostacyclin from veins given papa- 
verine prior to dissection. This could have been the 
effect of a more vasodilating effect on venous tissue 
than on arterial, maybe because of better penetration of 
papaverine through the thinner venous wall. This in turn 
would then lead to a lesser spasm during the operative 
procedure and lessened stimulation of the arachidonic 
pathway in the vascular wall. Another explanation may 
be that papaverine penetrated into the vessel wall and 
was released with the onset of vessel perfusion leading 
to interference with the assay. An experiment with I21 
would have given a definite answer to this question. 
When vessel segments are mounted in this perfusion 
setup. there is no vasoconstriction left, but we cannot 
rule out a certain amount of tension in the vessel wall. 
Data derived from cultured endothelial cells suggest 
papaverine to inhibit the arachidonic acid pathway at the 
phospholipase level (27 ). To study if the lessened release 
noted in the present study was a direct effect of 
papaverine on the endothelial cells. the next step was 
therefore to add papaverine directly to the perfusate. 
Using the 3H 6-keto-PGF,,, RIA method almost no re- 
Fig. 7 Scanning electron microscopy of a perfused mongrel dog carotid artery. Most of the endothelial cells are present. but home are folded and 
disrupted. (A) Magnification 103 times. (B) Magnification 629 times. 
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lease was seen, when venous segments were perfused 
without or with AA. This did not correspond with the 
concept that papaverine may inhibit the prostanoid 
production at the phospholipase level, whereas the 
cyclooxygenase should be unaffected. Furthermore, the 
theory that papaverine should block the release of the 
most potent vasodilator known, as well as simultane- 
ously prevent vasospasm, seemed unlikely. As the 
detectable amounts of 6-keto-PGF,, and TXB, were al- 
most abolished by papaverine when using ‘H RIA. a 
possible explanation might be that the assay was inter- 
fered with papaverine. A new radioimmunoassay with 
125I instead of ‘H tracer was therefore conducted where 
the pellet instead of the supematant was counted for 
radioactivity. The lZ51 assay displayed no difference in 
prostacyclin release between segments given papaverine 
to the perfusate and controls. The two assays use the 
same antibody and the same type of tracer but with dif- 
ferent types of radioactivity. It is well known that the use 
of derivatized tracers in immunoassay can alter the 
specificity of a method even in assays using the same 
antibody (28). Thus, although the known cross-reaction 
with other prostaglandins in both assays was similar, the 
observed discrepancy between results by the ‘H- and 
i2”I-based methods might be evidence of a difference in 
the cross-reactivity of an unidentified prostaglandin by 
the two methods. However, in perfusate samples both 
with and without added papaverine, HPLC followed by 
‘H RIA showed a single peak of immunoactivity which 
was associated with the elution time of 6-keto-PGF,, 
standard. Surprisingly, the apparent level of 6-keto- 
PGF,, in the perfusate with papaverine, which had pre- 
viously (i.e. before HPLC) been very low by the 3H- 
based assay, was now as high as with the iZ51-based 
method. This suggested that an interfering substance af- 
fecting only the 3H-based assay was being removed from 
this sample by the HPLC purification. Indeed, the addi- 
tion of papaverine (0.6 mg/ml) to the 3H immunoassay 
was shown to reduce the efficiency of the charcoal sus- 
pension in adsorbing the tracer. This accounts for the 
artefactually lowered estimates of 6-keto-PGF,, concen- 
tration in the presence of high levels of papaverine by 
the ‘H-based method. 
The fact that the cyclooxygenase inhibitor diclofenac 
failed to prevent the dilatatory effect of papaverine 
supports the above finding that the effects of papaverine 
are not mediated through the arachidonic acid cascade. 
No explicit test of TXB2 release using lZ51 tracer was 
performed, but the effect of papaverine also on TXB, 
release makes it likely to be explained by the same 
mechanism. 
In summary, this study first demonstrated that papa- 
verine does not influence the release of prostacyclin in 
canine arteries and probably not in canine veins and that 
the vasodilating effect of papaverine is not mediated 
via the prostaglandin pathway. Second, it illustrates 
the sensitivity of the charcoal separation technique of 
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